SCHEMBL4985368

SCHEMBL4985368

CCSc1cc(C)nc(SCC)c1NC(=O)CCCSc1nc2ccccc2s1

nearest known ligand 0.67

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 7/20 0.67
SMN1; SMN2 Q16637 5/20 0.67
POLB P06746 2/20 0.65
MAPT P10636 3/20 0.62
ALDH1A1 P00352 2/20 0.62
L3MBTL1 Q9Y468 2/20 0.62
HTT P42858 3/20 0.61
TP53 P04637 1/20 0.61
HPGD P15428 1/20 0.61
TSHR P16473 1/20 0.61
ALOX12 P18054 1/20 0.61
MAPK1 P28482 1/20 0.61
NPC1 O15118 2/20 0.58
RAB9A P51151 2/20 0.58
RECQL P46063 1/20 0.58
ATM Q13315 1/20 0.58
SOAT1 P35610 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4985347 0.98 LMNA (0.65) LMNASMN1; SMN2POLBMAPTALDH1A1
SCHEMBL4988095 0.97 LMNA (0.64) LMNASMN1; SMN2POLBMAPTALDH1A1
SCHEMBL4981691 0.97 LMNA (0.64) LMNASMN1; SMN2POLBMAPTALDH1A1
SCHEMBL4981905 0.97 LMNA (0.64) LMNASMN1; SMN2POLBMAPTALDH1A1
SCHEMBL4982610 0.97 LMNA (0.64) LMNASMN1; SMN2POLBMAPTALDH1A1
SCHEMBL4990028 0.89 NPC1 (0.69) LMNASMN1; SMN2POLBMAPTALDH1A1
SCHEMBL4984269 0.88 SOAT1 (0.72) LMNASMN1; SMN2POLBMAPTALDH1A1
SCHEMBL4989291 0.86 SOAT1 (0.70) LMNASMN1; SMN2POLBMAPTALDH1A1
SCHEMBL4984500 0.85 LMNA (0.65) LMNASMN1; SMN2POLBMAPTALDH1A1
SCHEMBL4981334 0.85 SOAT1 (0.69) LMNASMN1; SMN2POLBMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7414066-B2 Amide compounds and medications containing the same technical field KOWA COMPANY LTD. (JP) 2008-08-19 US disclosed
US-7393866-B2 Amide compounds and medications containing the same KOWA COMPANY, LTD. (JP) 2008-07-01 US disclosed
EP-0979823-B1 NOVEL AMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME KOWA CO (JP) 2006-03-29 EP disclosed
US-20050131002-A1 Novel amide compounds and medications containing the same KOWA COMPANY LTD. (JP) 2005-06-16 US disclosed
US-20050131001-A1 Novel amide compounds and medications containing the same technical field KOWA COMPANY LTD. (JP) 2005-06-16 US disclosed
US-6849647-B1 Amide compounds and medications containing the same technical field KOWA COMPANY, LTD. (JP) 2005-02-01 US disclosed
EP-0979823-A1 NOVEL AMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME Kowa Company Ltd. (JP) 2000-02-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050131001-A1 Novel amide compounds and medications containing the same technical field ACAT2, SULT2A1, ACAT1 LMNA 4703/4885SMN1; SMN2 2877/4885POLB 4033/4885
US-20050131002-A1 Novel amide compounds and medications containing the same ACAT2, SULT2A1, ACAT1 LMNA 4629/4885SMN1; SMN2 2534/4885POLB 4025/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.